ADC Therapeutics (ADC Therapeutics) Short-Term Debt : $0.00 Mil (As of Mar. 2024)

View and export this data going back to 2020. Start your Free Trial

What is ADC Therapeutics Short-Term Debt?

ADC Therapeutics's Short-Term Debt for the quarter that ended in Mar. 2024 was $0.00 Mil.

ADC Therapeutics's quarterly Short-Term Debt declined from Sep. 2023 ($14.33 Mil) to Dec. 2023 ($0.00 Mil) but then stayed the same from Dec. 2023 ($0.00 Mil) to Mar. 2024 ($0.00 Mil).

ADC Therapeutics's annual Short-Term Debt increased from Dec. 2021 ($6.58 Mil) to Dec. 2022 ($12.47 Mil) but then declined from Dec. 2022 ($12.47 Mil) to Dec. 2023 ($0.00 Mil).

ADC Therapeutics Short-Term Debt Historical Data

The historical data trend for ADC Therapeutics's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

ADC Therapeutics Short-Term Debt Chart

ADC Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

Get a 7-Day Free Trial

3.63

6.58

12.47

ADC Therapeutics Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Short-Term Debt	Get a 7-Day Free Trial															13.53	13.86	14.33	-	-

ADC Therapeutics Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

ADC Therapeutics Short-Term Debt Related Terms

Thank you for viewing the detailed overview of ADC Therapeutics's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

ADC Therapeutics (ADC Therapeutics) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » ADC Therapeutics SA (NYSE:ADCT) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

Route de la Corniche 3B, Biopole, Epalinges, CHE, 1066

Website

https://www.adctherapeutics.com

ADC Therapeutics SA is a commercial-stage oncology-focused biotechnology company. It is involved in the development of antibody-drug conjugates for patients suffering from hematological malignancies and solid tumors. The company's product candidate includes ZYNLONTA, camidanlumab tesirine, ADCT-602, ADCT-601, ADCT-901, ADCT-701 and ADCT-212.